SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over high capital expenditures in AI infrastructure and potential execution risks, fueling a volatile debate in the community about whether this represents a long-term value opportunity or a structural decline. While some traders are expressing extreme frustration over the stock's persistent underperformance relative to broader market indices, others are highlighting the company's strong cash flows and cloud leadership as reasons to view current price levels as an attractive entry point for the long term.

The Shrimp Army

The Shrimp Army is gaining traction as part of a broader trend of sea-themed memecoins, sparking intense debate among community members over its potential for rapid growth versus risks of being a speculative pump-and-dump. Traders are actively monitoring the token's ability to maintain upward momentum and consolidate at higher valuation levels.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing intense selling pressure as investors react to potential regulatory hurdles regarding prediction markets and ongoing legal challenges surrounding the NCAA. The community is heavily polarized, with many retail traders actively loading puts and voicing frustration over consistent insider selling while others view the pullback as a potential buying opportunity.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors debate whether the fund's parabolic run is driven by genuine exposure to high-growth AI and aerospace giants like SpaceX and Anthropic or if it has entered bubble territory due to its massive premium to Net Asset Value. The community remains sharply divided, with many actively hunting for alternative "catch-up" plays like DXYZ and RVI while others warn of a potential liquidity trap once lock-up periods expire.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as community members point to signs of quiet accumulation and a potential bullish reversal for the gaming token. Traders are actively debating the token's role in the future of on-chain gaming economies, with sentiment divided between optimism for a recovery and frustration over recent volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant downward pressure as investors react to a Google Research blog post regarding TurboQuant, an algorithmic compression method that some fear could reduce long-term demand for high-bandwidth memory. While the broader community is deeply divided between those viewing the sell-off as an algorithmic panic driven by misunderstanding and those concerned about cyclical memory sector headwinds, many retail traders are actively debating whether to accumulate shares on the dip or exit to avoid further downside.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is currently in the spotlight following a short-seller report from Culper Research that alleges channel stuffing and financial irregularities, which the company has formally dismissed as containing misleading and inaccurate statements. The community is actively debating the credibility of these allegations, with many long-term shareholders expressing strong conviction in management's integrity and focusing on upcoming earnings as a potential catalyst for a rebound.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is seeing heightened trading volume and community interest driven by persistent speculation regarding an upcoming SpaceX IPO, which remains a primary holding for the fund. Investors are actively debating the valuation premium relative to its net asset value compared to other proxies, while sentiment remains bullish on the fund's concentrated exposure to high-growth unicorns like Anthropic and OpenAI.

Intercontinental Exchange, Inc. engages in the provision of market infrastructure, data services and technology solutions. It operates through the following segments: Exchanges, Fixed Income and Data Services, and Mortgage Technology. The Exchanges segment operates marketplace technology for the listing, trading, and clearing of derivatives contracts and financial securities, as well as data and connectivity services. The Fixed Income and Data Services segment provides fixed income pricing, reference data, indices, analytics, and execution services as well as global credit default swap, or CDS, clearing, and multi-asset class data delivery technology. The Mortgage Technology segment provides a technology platform that offers digital workflow tools to address inefficiencies and mitigate risks that exist in the US residential mortgage market lifecycle from application through closing, servicing, and the secondary market. The company was founded by Jeffrey C. Sprecher in 2000 and is headquartered in Atlanta, GA.

Intercontinental Exchange Inc

Intercontinental Exchange (ICE) is currently the focus of market attention due to its strategic push into tokenized securities and its high-profile investment in Polymarket, which signals a broader Wall Street pivot toward on-chain infrastructure. Traders are closely monitoring the stock's potential for growth as the NYSE owner leans into digital asset innovation and institutional crypto adoption, with community sentiment shifting between excitement over these technological partnerships and caution regarding broader market volatility.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is facing significant volatility following a strategic one-billion-dollar investment in Nanya Technology and market reactions to Google's TurboQuant AI algorithm, which some investors fear could reduce long-term memory demand. While some in the community see the pullback as a buying opportunity in a supply-constrained sector, others remain wary of cyclical risks and the stock's recent parabolic run.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated a "buy" rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday...

<ul class="summary-bullets"><li>The start of the trial triggered a second $10 million milestone payment to Lexicon.</li><li>The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants.</li><li>The trial is expected to be completed in early 2027, Novo said.</li></ul>Novo Nordisk (NVO) is pushing deeper into next-gen obesity treatments. The drugmaker announced on Monday that it has initiated a Phase 1 study of LX9851, Lexicon Pharmaceuticals’ oral non-incretin drug candidate for obesity and related metabolic disorders.&nbsp;This adds to Novo’s obesity treatment pipeline, which also features the semaglutide injection, famously known as Wegovy.&nbsp;At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed 1%, while&nbsp;<a href="https://stocktwits.com/symbol/LXRX">Lexicon Pharmaceuticals’ (LXRX) stock</a> traded over 5% higher.<h2 class="st-heading-2">Novo’s $10 Million Milestone Payment To Lexicon</h2>The start of the trial triggered a second $10 million milestone payment to Lexicon under their licensing deal signed in March 2025. The agreement gives Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible to receive up to $1 billion in total milestone payments, as well as royalties on future sales.The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants. The trial is expected to be completed in early 2027.“LX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities,” said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk.&nbsp;<h2 class="st-heading-2">Lilly’s&nbsp;Experimental Diabetes Pill Outperforms Oral Semaglutide&nbsp;</h2>This comes days after&nbsp;Eli Lilly and Company (LLY) announced that its experimental diabetes pill, Orforglipron, outperformed oral semaglutide in a large Phase 3 study, delivering stronger reductions in blood sugar and greater weight loss over 52 weeks. Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.Drug developers are racing to tap the booming obesity market, currently led by injectables like Wegovy and Eli Lilly’s Zepbound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for NVO and LXRX remained in the ‘bearish’ zone over the past 24 hours.One user called LXRX’s price point “attractive.”<stembedurl>https://stocktwits.com/macrossluvsrobotech/message/648275638</stembedurl>Another user was skeptical about Novo’s forecast.<stembedurl>https://stocktwits.com/Golferhack12/message/648300759</stembedurl>Year-to-date, NVO stock fell 29% while LXRX shares have gained more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal

The trial is part of a licensing deal between Novo and Lexicon that allows Novo to develop and commercialize the drug.

Equity

XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study

Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.

Citigroup Forecasts Strong Price Appreciation for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Citigroup lifted their price objective on Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the company a "buy" rating in a report on Tuesday...

What is HC Wainwright's Estimate for LXRX Q1 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for Lexicon Pharmaceuticals in a report issued on Thursday, March 5th. HC...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.8% Following Earnings Beat

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.8% Following Earnings Beat...

FY2027 Earnings Forecast for LXRX Issued By HC Wainwright

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at HC Wainwright issued their FY2027 EPS estimates for Lexicon Pharmaceuticals in a research report issued on Thursday...

Lexicon Pharmaceuticals Q4 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) outlined progress across three late-stage programs and reported sharply lower operating expenses during its fourth-quarter and full-year 2025 earnings call held...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down - Should You Sell?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down - Should You Sell...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Current Price	$1.68
Prev Close	$1.72
Open	$1.72
Dividend Yield	0.00%
50-Day Moving Average	$1.48
Beta	1.63
Avg. Volume	2.5M
PE Ratio	-12.10

52-Week High	$1.83
52-Week Low	$0.325
Market Capitalization	$711.78M
EPS (Annual)	-$0.1387
Price to Book	5.68
Revenue Per Employee	$614,851.85

LXRX
Lexicon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXRX News

LXRXLexicon Pharmaceuticals Inc